{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"40"}],"units":"Participants"}],"description":"The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG000","title":"Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG001","title":"Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG002","title":"Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG003","title":"Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W"}],"paramType":"NUMBER","populationDescription":"Safety Population included all randomized participants who received at least 1 dose of study treatment. As outlined in the protocol, the objective was to examine the corneal events in Arms B to D, compared to Arm A; hence, Arm E was not included.","reportingStatus":"POSTED","timeFrame":"Up to 29.5 months","title":"Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}